Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
IonQ has achieved a significant technological advancement in partnership with the Air Force Research Lab (AFRL), demonstrating the ability to efficiently connect quantum computers over long distances.
Scholar Rock’s potential new SMA treatment, Apitegromab, received a delay from the FDA due to manufacturing site issues, not the drug's safety or effectiveness.
Wells Fargo significantly raised its rating and price target for CoreWeave, moving the stock to Overweight and citing "multiple" factors that signal strong growth potential.
Firefly Aerospace's first post-IPO report showed wider losses and lower revenue. The CEO claims "steady progress", noting they are increasing rocket production to meet strong demand for space launches, especially for national security missions.
Boeing is making major sales. China is about to order up to 500 planes as U.S. trade tensions ease. Separately, Uzbekistan Airways bought 14 huge Dreamliners with options for eight more (worth over $8 billion) to expand its international routes, including to the U.S.